Description and predictors of direct and indirect costs of pain reported by cancer patients

Journal of Pain and Symptom Management

Volumn 25, Issue 1, 2003, Pages 9-18

  Fortner, Barry V ^a,f   Demarco, Gail ^b   Irving, Gordon ^c   Ashley, Jeri ^a   Keppler, Ginny ^d   Chavez, Jana ^e   Munk, Jana ^b  

^a West Clinic   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c SWEDISH MEDICAL CENTER   (United States)

^d SWEDISH MEDICAL CENTER   (United States)

^e Medical Center   (United States)

^f West Clinic   (United States)

Author keywords

Cancer; Costs; Direct costs; Indirect costs; Neoplasm; Pain; Pain related costs

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CODEINE; DEXTROPROPOXYPHENE; FENTANYL; HYDROCODONE; HYDROMORPHONE; LEVORPHANOL; METHADONE; MORPHINE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL;

ADULT; AGED; ARTICLE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CHILD CARE; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; EMERGENCY TREATMENT; FEMALE; HOSPITAL COST; HOSPITALIZATION; HOUSEHOLD; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICAL FEE; PAIN ASSESSMENT; PATIENT INFORMATION; PATIENT TRANSPORT; QUESTIONNAIRE; RACE DIFFERENCE;

FORECASTING; HEALTH CARE COSTS; HUMANS; NEOPLASMS; PAIN; PALLIATIVE CARE;

EID: 0037247681     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(02)00597-3     Document Type: Article

References (44)

1. Jacox A., Carr D.B., Payne R.et al. Management of cancer pain. Clinical practice guideline no. 9. 1994;Agency for Health Care Policy and Research, Rockville, MD.
2. Bonica J. Cancer pain. Bonica J. The management of pain, vol.1. 2nd ed:1990;400-414 Lea and Febiger, Philadelphia.
3. Portenoy R.K. Cancer pain. Epidemiology and syndromes. Cancer. 63(11 Suppl):1989;2298-2307.
4. Cleeland C. The impact of pain on the patient with cancer. Cancer. 54:1984;2635-2641.
5. Ahles T.A., Blanchard E.B., Ruckdeschel J.C. The multidimensional nature of cancer-related pain. Pain. 17(3):1983;277-288.
6. Daut R.L., Cleeland C.S. The prevalence and severity of pain in cancer. Cancer. 50(9):1982;1913-1918.
7. Derogatis L.R., Morrow G.R., Fetting J.et al. The prevalence of psychiatric disorders among cancer patients. JAMA. 249(6):1983;751-757.
8. Portenoy R.K., Kornblith A.B., Wong G.et al. Pain in ovarian cancer patients. Prevalence, characteristics, and associated symptoms. Cancer. 74(3):1994;907-915.
9. Portenoy R.K., Payne D., Jacobsen P. Breakthrough pain. characteristics and impact in patients with cancer pain Pain. 81(1-2):1999;129-134.
10. Chandler S., Payne R. Economics of unrelieved cancer pain. Am J Hospice Palliative Care. 15(4):1998;223-226.
11. Ferrell B. Cost issues surrounding the treatment of cancer related pain. J Pharm Care Pain Symptom Control. 1(1):1993;9-23.
12. Ferrell B., Schaffner M. Pharmacoeconomics and medical outcomes in pain management. Sem Anesth. 16(2):1997;152-159.
13. Ferrell B.R., Rhiner M. Use of technology in the management of cancer pain. J Pharm Care Pain Symptom Control. 2(1):1994;17-34.
14. American Cancer Society. Costs of Cancer. http://www2.cancer.org/cid/506.00/index.htm .
15. Finkler S.A. The distinction between cost and charges. Ann Intern Med. 96(1):1982;102-109.
16. Brown M.L. The national economic burden of cancer. an update J Natl Cancer Inst. 82(23):1990;1811-1814.
17. Moore K. Out-of-pocket expenditures of outpatients receiving chemotherapy. Oncol Nurs For. 25(9):1998;1615-1622.
18. Hillner B.E., McDonald M.K., Desch C.E.et al. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort. J Clin Oncol. 16(4):1998;1420-1424.
19. Stevens R.A., Ghazi S.M. Routes of opioid analgesic therapy in the management of cancer pain. Cancer Control. 7(2):2000;132-141.
20. Goughnour B.R., Arkinstall W.W. Potential cost-avoidance with oral extended-release morphine sulfate tablets versus morphine sulfate solution. Am J Hosp Pharm. 48(1):1991;101-104.
21. Ferrell B.R., Griffith H. Cost issues related to pain management. report from the Cancer Pain Panel of the Agency for Health Care Policy and Research J Pain Symptom Manage. 9(4):1994;221-234.
22. Kwan J.W. Use of infusion devices for epidural or intrathecal administration of spinal opioids. Am J Hosp Pharm. 47(8 Suppl):1990;S18-S23.
23. Bedder M.D., Burchiel K., Larson A. Cost analysis of two implantable narcotic delivery systems. J Pain Symptom Manage. 6(6):1991;368-373.
24. Zhukovsky D.S., Gorowski E., Hausdorff J.et al. Unmet analgesic needs in cancer patients. J Pain Symptom Manage. 10(2):1995;113-119.
25. Grant M., Ferrell B.R., Rivera L.M.et al. Unscheduled readmissions for uncontrolled symptoms. A health care challenge for nurses. Nurs Clin North Am. 30(4):1995;673-682.
26. Stommel M., Given C.W., Given B.A. The cost of cancer home care to families. Cancer. 71(5):1993;1867-1874.
27. Daut R.L., Cleeland C.S., Flanery R.C. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 17(2):1983;197-210.
28. Ferrell B.R. The technology of pain relief. Nurs Econ. 11(1):1993;52-54.
29. Williams R.M. Distribution of emergency department costs. Ann Emergency Med. 28(6):1996;671-676.
30. Williams R.M. The costs of visits to emergency departments. New Engl J Med. 334(10):1996;642-646.
31. Doolittle G.C., Harmon A., Williams A.et al. A cost analysis of a tele-oncology practice. J Telemedicine Telecare. 3(Suppl 1):1997;20-22.
32. Cardinale V. Drug topics red book. 2000;Medical Economics Company, Inc, Montvale, NJ.
33. Portenoy R.K., Hagen N.A. Breakthrough pain. definition, prevalence and characteristics Pain. 41:1990;273-282.
34. Blom G. Statistical estimates and transformed beta-variables. 1958;John Wiley and Sons, New York.
35. Serlin R.C., Mendoza T.R., Nakamura Y.et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 61(2):1995;277-284.
36. U. S. Bureau of the Census. Population Profile of the United State: 1997. Washington, DC: U. S. Government Printing Office, 1998.
37. Risberg T., Kaasa S., Wist E.et al. Why are cancer patients using non-proven complementary therapies? A cross-sectional multicentre study in Norway. Eur J Cancer. 33(4):1997;575-580.
38. Oneschuk D., Fennell L., Hanson J.et al. The use of complementary medications by cancer patients attending an outpatient pain and symptom clinic. J Palliat Care. 14(4):1998;21-26.
39. Miller M., Boyer M.J., Butow P.N.et al. The use of unproven methods of treatment by cancer patients. Frequency, expectations and cost. Support Care Cancer. 6(4):1998;337-347.
40. Holland J.C. Use of alternative medicine - a marker for distress? N Engl J Med. 340(22):1999;1758-1759.
41. Benbassat J., Taragin M. Hospital readmissions as a measure of quality of health care. advantages and limitations Arch Intern Med. 160(8):2000;1074-1081.
42. Jennett B. High technology medicine. Benefits and burdens:1986;Oxford University Press, New York.
43. Cox B.G., Cohen S.B. Methodological issues for health care surveys. 1985;Marcel Dekker, New York.
44. Lansing J.B., Morgan J.N. Economic survey methods. 1971;University of Michigan Press, Ann Arbor.